DiagnoCure to Host Q1 2009 Earnings Conference Call and Webcast

    Ticker Symbol: CUR

    QUEBEC CITY, March 3 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, announced today that the Company will release
its first quarter 2009 financial results on March 17, 2009, at approximately
4:30 p.m. (EDT). This release will be followed by a conference call, which
will be held on March 18, 2009, at 10:00 a.m. (EDT). The conference will begin
with a brief presentation, followed by a question-and-answer period.
    The event will be webcast live through DiagnoCure's website at
www.diagnocure.com, through a link on the Investors page - Presentations and
Conferences.
    For those who wish to take part in the conference call for the Q&A
period, please dial (514) 807-8791 (Montreal area), (416) 644-3419 (Toronto
area) or the toll-free number (800) 731-5319.
    For those unable to participate, a replay of the audio conference will
also be available on DiagnoCure's website as of March 19, 2008, also through a
link on the Investors page - Presentations and Conferences.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,
launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the
first GCC-based molecular test for the management of colorectal cancer. A
major study published in the February 18, 2009, edition of the JAMA ("Journal
of the American Medical Association") demonstrated that GCC, to which
DiagnoCure secured exclusive worldwide diagnostic rights, is the strongest
independent predictor of colorectal cancer recurrence. The Company also has a
strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and
commercialization of a second-generation prostate cancer test using PCA3,
DiagnoCure's proprietary molecular marker. This test is also available through
laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from
Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in
Canada. In addition to its own research, the Company intends to acquire or
in-license additional promising cancer biomarkers from both academic and
commercial institutions. For more information, visit www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF

For further information: Investors: J. F. Bureau, CFA, Sr. Vice
President and CFO, DiagnoCure Inc., (418) 527-6100,
communications@diagnocure.com; Media: Isabelle Taschereau, Associate Director,
Corporate Affairs, DiagnoCure Inc., (418) 527-6100,
i.taschereau@diagnocure.com